u/tb500_tangent

this is the specific case that made me start checking. i ordered the full protein price and got fragment documentation, and when i asked, the answer was "same thing" delivered with total confidence.

Independent result added to the log — there are very few on that compound.

Correction: that name covers two different molecules and the thread has been discussing both as one.

Right, and the concentration genuinely can differ from the branded product, which breaks people’s arithmetic.

Correction: SURMOUNT is the obesity programme and SURPASS is the diabetes one. The figure you quoted belongs to the other one.

This. Intention-to-treat versus completer analysis routinely moves the headline by several points.

For any compound with a thin testing history, identity is the first question. Mass spectrometry against a theoretical mass answers it; an area-percent purity figure does not.

Argued for a week about a result and then read the limitations section, which conceded most of my opponent’s point.

Which trial, and which arm?

The discontinuation numbers were the most useful thing in the paper for me and they were in a supplementary table.

What reference standard was the assay run against?

Why "compounded" is not "generic", written out because the confusion is constant.

A generic is an approved product demonstrated to be bioequivalent to a reference. A compounded preparation is made for a patient or, in the case of an outsourcing facility, under a different regulatory route entirely. It carries no equivalence claim and it is not required to demonstrate one.

That is not a quality judgement. Plenty of compounded preparations are made carefully in facilities with real testing programmes. It is a statement about what has and has not been established, and the difference matters when people assume the two are interchangeable.

personal import rules are not the same as commercial import rules

Standing reminder: research-use-only material is not approved for human use, and no outcome claims without evidence.

Spent an evening with the appendix tables and found the subgroup detail that the entire thread had been speculating about.

regional stock removes the question entirely

coa_forgery_watch is right that regional stock is the structural answer rather than a trick.

This. Ordering from regional stock takes the entire question off the table, which is why it comes up in every one of these threads.

Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.

Independent result added to the log — there are very few on that compound.

a press release is not a publication

milan_mensah is right about the programme names. They are different populations with different endpoints.

Citation requested rather than removal.

Agreed — and the preclinical to clinical gap is where nearly all the overclaiming happens.

research-use-only material is not approved for human use

Not convinced. You are comparing a compounded concentration with a branded one and assuming they match.

Which country, and which country did it ship from?

purity methods differ between compound classes

Independent result added to the log — there are very few on that compound.

Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.

Left up. Identity-first reasoning with a method stated, which is the standard for this board.

Independent result added to the log — there are very few on that compound.

What jurisdiction are you asking about?

rosa_almeida is right that a pure something-else is still something else.

Independent result added to the log — there are very few on that compound.

Relative risk reduction without the baseline rate is uninterpretable. A large relative reduction on a small absolute risk is a small absolute benefit.

Not convinced. Cross-trial comparison between two programmes with different populations and designs is not a comparison.

Independent result added to the log — there are very few on that compound.

Went looking for the registered protocol to see whether the endpoint had changed.

Adding the check nobody runs — the registered protocol is public and takes two minutes to compare.

Ask for the theoretical mass alongside the measured one. It is a one-line addition to a certificate and it converts a purity claim into an identity claim.

Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.

Disagree — a 503B being registered does not make its preparations equivalent to an approved product. Different regulatory category entirely.

Is that a clinical claim or a preclinical one?

On concentration, which is where I see people actually get hurt.

A compounded vial can be filled at a different concentration from the branded product you were previously using. If you carry over your old arithmetic — same number of units, different mg/mL — you draw a different amount and may not notice for weeks.

Read the label every time you switch. Redo the arithmetic on paper. Write the concentration on the vial. It is the same habit c/reconstitution keeps preaching and this is the case where it actually bites.